Medical Pharmacology: Chapter 37 — Antifungal Agents -- Module 1 — Polyene Antifungals: Amphotericin B Formulations and Nystatin

Chapter 37 — Antifungal Agents — Module 1 — Polyene Antifungals: Amphotericin B Formulations and Nystatin

1. Amphotericin B exerts its antifungal effect through which of the following mechanisms?

A) Inhibition of lanosterol 14-alpha-demethylase, blocking the final steps of ergosterol biosynthesis
B) Binding to ergosterol in the fungal cell membrane and self-assembling into transmembrane pores that cause non-selective ion flux
C) Competitive inhibition of beta-1,3-glucan synthase, disrupting fungal cell wall integrity
D) Intercalation into fungal DNA, inhibiting topoisomerase II and blocking replication
E) Inhibition of squalene epoxidase, depleting ergosterol precursors in the biosynthetic pathway

ANSWER: B

Rationale:

Amphotericin B (AmB) does not inhibit ergosterol biosynthesis; it acts downstream by binding directly to ergosterol already incorporated into the fungal cell membrane. The drug's amphipathic macrolide structure — a hydrophobic polyene face opposite a hydrophilic polyhydroxyl chain — allows it to insert into the lipid bilayer alongside ergosterol molecules. Multiple AmB molecules self-assemble around ergosterol into barrel-shaped oligomeric pore structures approximately 0.4 to 0.8 nanometers in diameter. These transmembrane pores permit passive, non-selective flux of monovalent cations (potassium, sodium, hydrogen), dissipating the membrane electrochemical gradient and driving rapid cellular depolarization, loss of nutrient import capacity, and cell death.

Option A: Option A is incorrect because lanosterol 14-alpha-demethylase inhibition is the mechanism of the azole antifungals (fluconazole, voriconazole, and related agents), not the polyenes.
Option C: Option C is incorrect because beta-1,3-glucan synthase inhibition is the mechanism of the echinocandin class (caspofungin, micafungin, anidulafungin).
Option D: Option D is incorrect; DNA intercalation and topoisomerase inhibition describe mechanisms of antibacterial agents such as fluoroquinolones and certain antineoplastic agents, not antifungals.
Option E: Option E is incorrect because squalene epoxidase inhibition is the mechanism of the allylamine class (terbinafine), not the polyenes.

2. Amphotericin B deoxycholate is correctly characterized by which of the following statements regarding its origin and molecular structure?

A) It is a synthetic triazole compound developed through combinatorial chemistry with a fluorinated pyrimidine ring
B) It is a lipopeptide produced by Pseudomonas fluorescens with three fatty acid side chains that anchor into fungal membranes
C) It is a cyclic hexapeptide derived from Glarea lozoyensis that inhibits ergosterol synthesis by blocking squalene cyclization
D) It is a macrolide polyene antibiotic produced by Streptomyces nodosus, featuring a large lactone ring with seven conjugated double bonds on its hydrophobic face
E) It is a semisynthetic echinocandin produced by modifying a pneumocandin natural product from Zalerion arboricola

ANSWER: D

Rationale:

Amphotericin B is a naturally occurring macrolide polyene antibiotic isolated from Streptomyces nodosus in 1955. Its molecular architecture consists of a large macrolide lactone ring with a rigid hydrophobic face bearing seven conjugated double bonds — the heptaene system that gives the polyene class its name — opposite a hydrophilic polyhydroxyl chain. This amphipathic structure is essential for membrane interaction: the polyene face inserts into the fungal lipid bilayer and self-assembles around ergosterol to form transmembrane pores.

Option A: Option A is incorrect; synthetic triazoles (fluconazole, voriconazole, itraconazole) are not polyene antibiotics and are not produced by Streptomyces species.
Option B: Option B is incorrect; lipopeptides from Pseudomonas species describes daptomycin-class antibacterial agents, not antifungals, and the described mechanism does not apply to AmB.
Option C: Option C is incorrect; cyclic hexapeptide structures blocking squalene cyclization do not describe any clinically used antifungal class; the echinocandins are cyclic hexapeptides but target glucan synthesis.
Option E: Option E is incorrect; the echinocandins (caspofungin, micafungin, anidulafungin) are the semisynthetic cyclic lipopeptides, and caspofungin is derived from pneumocandin B0 from Glarea lozoyensis — this is the correct origin for an echinocandin, not for AmB.

3. Which of the following best describes the fungicidal versus fungistatic activity of amphotericin B across clinically relevant pathogens?

A) Amphotericin B is fungicidal against susceptible Candida species and Cryptococcus neoformans, and fungistatic against Aspergillus species and most molds
B) Amphotericin B is fungistatic against all clinically relevant pathogens at standard therapeutic doses and achieves fungicidal activity only at supra-therapeutic concentrations
C) Amphotericin B is fungicidal against Aspergillus fumigatus and fungistatic against Candida species due to differential ergosterol content in hyphal versus yeast forms
D) Amphotericin B is uniformly fungicidal against all organisms within its spectrum of activity, which is the primary pharmacodynamic advantage over the azole class
E) Amphotericin B is fungistatic against Cryptococcus neoformans when used as monotherapy and requires combination with flucytosine to achieve fungicidal killing

ANSWER: A

Rationale:

At concentrations achieved with standard clinical dosing, amphotericin B is fungicidal against susceptible yeast-form pathogens — including Candida species and Cryptococcus neoformans — and fungistatic against Aspergillus species and most molds. This distinction is clinically meaningful: for candidemia and cryptococcal meningitis, AmB's superior killing kinetics compared to azoles have direct therapeutic implications, particularly in immunocompromised hosts where host defenses cannot compensate for fungistatic activity alone.

Option B: Option B is incorrect; AmB does achieve fungicidal activity against yeasts at standard doses, not only at supra-therapeutic concentrations.
Option C: Option C inverts the correct pattern: AmB is fungicidal against yeasts (Candida, Cryptococcus), not against Aspergillus, and fungistatic against molds, not against Candida.
Option D: Option D is incorrect; the claim of uniform fungicidal activity across all organisms in spectrum is factually wrong — the fungistatic activity against Aspergillus and other molds is well established.
Option E: Option E is incorrect; AmB used as monotherapy is fungicidal against Cryptococcus neoformans. The combination of AmB with flucytosine (5-FC) is standard for cryptococcal meningitis induction because it is synergistic and achieves more rapid CSF sterilization, but AmB alone does have fungicidal activity against Cryptococcus.

4. The selective toxicity of amphotericin B for fungal rather than mammalian cells is best explained by which of the following?

A) Fungal cells lack the cholesterol transporter proteins required to incorporate amphotericin B into mammalian-type cell membranes, making drug binding impossible in host tissues
B) Amphotericin B is actively effluxed from mammalian cells by P-glycoprotein before pore formation can occur, whereas fungal cells lack this efflux mechanism
C) Amphotericin B binds ergosterol with approximately 10-fold higher affinity than it binds cholesterol, providing relative but not absolute selectivity for fungal cell membranes
D) Mammalian cell membranes contain sphingomyelin sheaths that physically exclude amphotericin B molecules before they can contact cholesterol, providing complete protection from pore formation
E) Ergosterol has a unique hydroxyl group configuration at the C-7 position absent in cholesterol that creates a specific high-affinity binding pocket that accommodates only the polyene macrolide ring

ANSWER: C

Rationale:

The pharmacological basis for the selective fungal toxicity of amphotericin B is that it binds ergosterol with approximately 10-fold higher affinity than it binds cholesterol, the principal sterol in mammalian cell membranes. This differential affinity explains why therapeutic concentrations of AmB preferentially disrupt fungal membranes while producing limited interaction with host cell membranes. Critically, this selectivity is relative, not absolute: at the concentrations required for clinical efficacy, AmB does interact with cholesterol in mammalian cell membranes, and this interaction is the mechanistic basis for nephrotoxicity, infusion reactions, and electrolyte disturbances. The renal tubular epithelium is particularly vulnerable because it is exposed to high luminal drug concentrations and bears cholesterol-rich apical membranes.

Option A: Option A is incorrect; the concept of cholesterol transporter proteins preventing AmB binding is not an established mechanism and misrepresents the pharmacology.
Option B: Option B is incorrect; P-glycoprotein efflux of AmB from mammalian cells is not a recognized mechanism of selective toxicity.
Option D: Option D is incorrect; sphingomyelin sheaths do not provide complete protection from AmB and this is not a recognized mechanism of mammalian cell protection.
Option E: Option E is incorrect; while structural differences between ergosterol and cholesterol do account for differential binding affinity, the specific description of a C-7 hydroxyl binding pocket is an inaccurate fabrication.

5. A pharmacist preparing amphotericin B deoxycholate for IV infusion asks about the correct diluent. Which of the following statements about amphotericin B deoxycholate administration is correct?

A) Amphotericin B deoxycholate can be administered orally for deep-seated infections when the patient is unable to tolerate IV access, as gastrointestinal absorption at high doses is approximately 30%
B) Amphotericin B deoxycholate should be diluted in normal saline (0.9% NaCl) to maintain the deoxycholate micelle complex and prevent aggregation of drug particles
C) Amphotericin B deoxycholate is administered as a rapid IV push over 5 to 10 minutes to avoid prolonged exposure of the renal vasculature to high drug concentrations
D) Amphotericin B deoxycholate penetrates the gastrointestinal mucosa poorly but achieves therapeutic serum levels within 4 hours after oral administration in fasting patients
E) Amphotericin B deoxycholate is formulated for intravenous use only because it is not absorbed from the gastrointestinal tract, and must be diluted in 5% dextrose in water because saline causes precipitation of the drug

ANSWER: E

Rationale:

Amphotericin B deoxycholate is not absorbed from the gastrointestinal tract and therefore cannot be used orally for systemic fungal infections. It requires intravenous administration. The correct diluent is 5% dextrose in water (D5W); normal saline (0.9% NaCl) must not be used because electrolytes in saline disrupt the deoxycholate micellar complex, causing the drug to precipitate. The drug is infused slowly over 2 to 4 hours — not as a rapid IV push — to limit the rate of infusion-related reactions.

Option A: Option A is incorrect; AmBd has no meaningful oral bioavailability and is not used orally for systemic infections under any clinical circumstances.
Option B: Option B inverts the correct diluent: saline causes precipitation rather than maintaining the micellar complex, and D5W is required.
Option C: Option C is incorrect; rapid IV push is contraindicated, not recommended — slow infusion over 2 to 4 hours is the standard approach and is important for tolerability.
Option D: Option D is incorrect; AmBd does not achieve therapeutic serum levels after oral administration under any circumstances; the premise of option D is pharmacologically false.

6. A patient with acute myeloid leukemia develops fungemia during induction chemotherapy. Blood cultures grow a Candida species identified as Candida lusitaniae. Which of the following statements correctly characterizes the susceptibility of this organism to amphotericin B?

A) Candida lusitaniae is uniformly susceptible to amphotericin B and should be treated with standard doses of liposomal amphotericin B as first-line therapy
B) Candida lusitaniae demonstrates intrinsic resistance to amphotericin B through constitutive ERG3 gene mutations, resulting in reduced ergosterol content in the cell membrane and making amphotericin B unreliable for treatment
C) Candida lusitaniae develops amphotericin B resistance only after prolonged exposure and is therefore appropriate for short-course amphotericin B induction therapy followed by azole step-down
D) Candida lusitaniae resistance to amphotericin B is a class effect that extends to all polyene antifungals including nystatin, but the organism remains susceptible to the echinocandins and all azole agents
E) Candida lusitaniae is susceptible to amphotericin B at standard minimum inhibitory concentrations but requires combination with flucytosine to achieve adequate clinical cure rates in fungemia

ANSWER: B

Rationale:

Candida lusitaniae is one of the most important exceptions to the broad Candida susceptibility to amphotericin B. It demonstrates intrinsic resistance through constitutive ERG3 gene mutations that alter ergosterol biosynthesis, resulting in membranes with reduced ergosterol content and therefore reduced drug-binding target. Because ergosterol is the pharmacological target of amphotericin B, depletion of ergosterol from the membrane eliminates the drug's mechanism of action. This intrinsic resistance means that empirical polyene therapy will fail in patients with C. lusitaniae fungemia, and this organism can be misidentified as other Candida species by some automated identification systems, making species-level identification critical. Alternative therapy — typically an echinocandin or azole based on susceptibility testing — is required.

Option A: Option A is incorrect; C. lusitaniae is not uniformly susceptible to AmB; the statement reverses the correct clinical guidance.
Option C: Option C is incorrect; resistance in C. lusitaniae is intrinsic and constitutive, not acquired with prolonged exposure, and short-course AmB induction is not appropriate.
Option D: Option D is incorrect as stated: while AmB resistance in C. lusitaniae is an actionable clinical fact, sweeping claims about all azoles and echinocandins remaining uniformly susceptible are not warranted — susceptibility testing is always required given the multidrug-resistant potential of this species in some settings.
Option E: Option E is incorrect; C. lusitaniae does not have merely elevated MICs requiring combination rescue — it has genuine intrinsic polyene resistance.

7. Which of the following correctly describes the distribution pharmacokinetics of amphotericin B deoxycholate after intravenous administration?

A) Amphotericin B deoxycholate has a small volume of distribution of approximately 0.1 L/kg, remaining largely confined to the plasma compartment with minimal tissue penetration
B) Amphotericin B deoxycholate achieves cerebrospinal fluid concentrations of approximately 50% of simultaneous plasma concentrations, making it highly effective for CNS fungal infections through CSF penetration alone
C) Amphotericin B deoxycholate is minimally protein-bound (less than 10%) in plasma, which accounts for its rapid renal filtration and short elimination half-life of approximately 6 hours
D) Amphotericin B deoxycholate is highly protein-bound in plasma (greater than 90%), has a large volume of distribution of approximately 4 L/kg, and achieves CSF concentrations of less than 4% of plasma concentrations
E) Amphotericin B deoxycholate distributes preferentially into adipose tissue and skeletal muscle, with minimal accumulation in the liver, spleen, kidneys, and adrenal glands

ANSWER: D

Rationale:

Amphotericin B deoxycholate is highly protein-bound in plasma, primarily to lipoproteins including low-density lipoprotein and high-density lipoprotein, with protein binding exceeding 90%. Despite this high protein binding, the volume of distribution is large at approximately 4 L/kg, indicating extensive tissue penetration into metabolically active organs including the liver, spleen, lungs, kidneys, and adrenal glands. Central nervous system penetration is poor: CSF concentrations are typically less than 4% of simultaneous plasma concentrations following standard IV dosing. Despite this limited CSF penetration, AmBd was the standard treatment for cryptococcal meningitis for decades, likely because high drug concentrations accumulate in the choroid plexus and meninges themselves.

Option A: Option A inverts the correct volume of distribution: AmBd has a large Vd of approximately 4 L/kg, not a small Vd of 0.1 L/kg; the small Vd description would suggest plasma confinement, which is incorrect.
Option B: Option B is incorrect because it grossly overstates CSF penetration: approximately 50% of plasma concentrations is not achievable with standard systemic AmBd dosing; the true figure is less than 4%.
Option C: Option C inverts protein binding: AmBd is greater than 90% protein-bound, not less than 10%, and the elimination half-life is approximately 15 days (reflecting slow release from deep tissue compartments), not 6 hours.
Option E: Option E incorrectly identifies the primary distribution sites; AmBd distributes extensively into the reticuloendothelial organs (liver, spleen) and kidneys, not primarily into adipose tissue and skeletal muscle.

8. A transplant patient receiving tacrolimus develops invasive aspergillosis and requires antifungal therapy. Which of the following statements correctly characterizes the drug interaction profile of amphotericin B deoxycholate with tacrolimus?

A) Amphotericin B deoxycholate is not metabolized by cytochrome P450 enzymes and does not inhibit or induce CYP isoforms, so there are no pharmacokinetic interactions with tacrolimus; however, the two agents produce additive nephrotoxicity through independent pharmacodynamic mechanisms
B) Amphotericin B deoxycholate is a potent inhibitor of CYP3A4 and markedly increases tacrolimus plasma concentrations, requiring immediate tacrolimus dose reduction of approximately 50% before initiating antifungal therapy
C) Amphotericin B deoxycholate induces CYP3A4 and substantially lowers tacrolimus trough levels, creating a high risk of acute rejection unless tacrolimus doses are empirically doubled
D) Amphotericin B deoxycholate competes with tacrolimus for binding to P-glycoprotein efflux transporters at the blood-brain barrier, increasing CNS exposure to both agents and requiring therapeutic drug monitoring of CSF tacrolimus levels
E) Amphotericin B deoxycholate undergoes hepatic glucuronidation by UGT enzymes and shares a common metabolic pathway with tacrolimus, resulting in competitive inhibition that requires dose adjustment of both agents

ANSWER: A

Rationale:

Amphotericin B is not significantly metabolized by cytochrome P450 enzymes and does not inhibit or induce CYP isoforms. This is a clinically important advantage over the azole antifungals, which are potent CYP inhibitors capable of markedly increasing tacrolimus plasma concentrations and precipitating calcineurin inhibitor toxicity. With AmB, the interaction with tacrolimus is pharmacodynamic rather than pharmacokinetic: both agents are independently nephrotoxic, and their concurrent use produces additive or synergistic nephrotoxicity. Tacrolimus causes afferent arteriolar vasoconstriction through calcineurin inhibition-mediated reduction in vasodilatory prostaglandins, which compounds the vasoconstriction and tubular toxicity of AmBd. This pharmacodynamic interaction is one of the primary indications for using a lipid formulation (L-AmB or ABLC) rather than AmBd in transplant recipients.

Option B: Option B is incorrect; AmBd is not a CYP3A4 inhibitor and does not increase tacrolimus concentrations through pharmacokinetic mechanisms.
Option C: Option C is incorrect; AmBd does not induce CYP3A4 and does not lower tacrolimus levels through enzyme induction.
Option D: Option D is incorrect; P-glycoprotein competition between AmB and tacrolimus at the blood-brain barrier is not a recognized mechanism of interaction and CSF tacrolimus monitoring is not a clinical practice.
Option E: Option E is incorrect; AmBd does not undergo significant UGT glucuronidation and does not share a common metabolic pathway with tacrolimus.

9. An infectious disease consultant is asked about the standard dosing range for amphotericin B deoxycholate in a patient with invasive candidiasis and no baseline renal impairment. Which of the following correctly states the standard and maximum doses?

A) The standard dose is 0.1 to 0.25 mg/kg/day, with a maximum of 0.5 mg/kg/day reserved for immunocompromised patients; higher doses are not used because nephrotoxicity becomes universal above 0.5 mg/kg/day
B) The standard dose is 1.5 to 2.0 mg/kg/day, which is necessary to maintain plasma concentrations above the minimum inhibitory concentration for Candida species throughout the dosing interval
C) The standard dose is 0.5 to 1.0 mg/kg/day intravenously, with the upper range of 1.0 to 1.5 mg/kg/day reserved for life-threatening infections such as cryptococcal meningitis induction therapy and invasive mold infections
D) The standard dose is 3 to 5 mg/kg/day, equivalent to the dosing used for liposomal amphotericin B, because the deoxycholate vehicle requires proportionally higher doses to match lipid formulation tissue concentrations
E) The standard dose is 0.5 mg/kg/day regardless of the severity or site of infection, and dose escalation is not supported by clinical evidence and increases nephrotoxicity without improving outcomes

ANSWER: C

Rationale:

The standard dose of amphotericin B deoxycholate for most systemic fungal infections is 0.5 to 1.0 mg/kg per day administered intravenously. For life-threatening infections including cryptococcal meningitis induction therapy and invasive mold infections such as mucormycosis, doses of 1.0 to 1.5 mg/kg per day may be used, reflecting the need for maximal antifungal activity in infections with high mortality. A test dose of 1 mg over 20 to 30 minutes was historically used prior to the first full infusion but has fallen out of favor at many centers.

Option A: Option A understates the standard dose substantially; 0.1 to 0.25 mg/kg/day is well below therapeutic range and would be inadequate for invasive fungal infection.
Option B: Option B overstates the standard dose; 1.5 to 2.0 mg/kg/day exceeds the typical therapeutic range for AmBd and is not standard practice — at these doses nephrotoxicity is severe and dose-limiting without commensurate efficacy gain.
Option D: Option D confuses the dosing scales for AmBd and liposomal AmB; L-AmB is dosed at 3 to 5 mg/kg/day precisely because a higher absolute dose is required to match the efficacy of AmBd due to differences in bioavailability from the liposomal carrier — AmBd and L-AmB are never dosed identically.
Option E: Option E incorrectly states that 0.5 mg/kg/day is invariant regardless of infection severity; dose titration to 1.0 to 1.5 mg/kg/day for severe infections is supported by clinical practice guidelines.

10. Which of the following correctly describes the physical structure and pharmacokinetic rationale of liposomal amphotericin B (L-AmB)?

A) L-AmB consists of ribbon-like lipid bilayer sheets approximately 1.6 to 11 micrometers in length in which amphotericin B is intercalated at a 1:1 drug-to-lipid molar ratio, resulting in rapid uptake by the mononuclear phagocyte system
B) L-AmB consists of disk-shaped cholesteryl sulfate complexes approximately 120 to 140 nanometers in diameter that carry amphotericin B through the bloodstream and release it preferentially at sites of infection through complement-mediated disruption
C) L-AmB is a micellar suspension identical in structure to amphotericin B deoxycholate but at a higher drug concentration, which reduces the volume of distribution and limits renal tubular exposure
D) L-AmB is formulated as large multilamellar vesicles greater than 500 nanometers in diameter that are rapidly phagocytosed by alveolar macrophages, explaining its high pulmonary drug concentrations and superiority for invasive pulmonary aspergillosis
E) L-AmB consists of small unilamellar liposomes approximately 80 to 100 nanometers in diameter in which amphotericin B is intercalated into the phospholipid bilayer, shielding the drug from contact with cholesterol in renal tubular membranes while allowing delivery to fungal infection sites

ANSWER: E

Rationale:

Liposomal amphotericin B (L-AmB; AmBisome) consists of small unilamellar liposomes approximately 80 to 100 nanometers in diameter. Amphotericin B is intercalated into the phospholipid bilayer of the liposome membrane alongside cholesterol and distearoylphosphatidylglycerol. The liposomal membrane physically shields the encapsulated AmB from contact with cholesterol in mammalian cell membranes, reducing interaction with renal tubular epithelium while allowing preferential drug delivery to fungal infection sites where the liposomal structure is disrupted by fungal phospholipases and high local ergosterol concentrations. L-AmB achieves substantially higher plasma concentrations than AmBd at equivalent doses because liposomal encapsulation prolongs circulation time and reduces renal uptake.

Option A: Option A describes amphotericin B lipid complex (ABLC), not L-AmB; ABLC consists of ribbon-like lipid bilayer structures 1.6 to 11 micrometers in length that undergo MPS uptake, yielding high liver, spleen, and lung concentrations.
Option B: Option B describes amphotericin B colloidal dispersion (ABCD), which consists of disk-shaped cholesteryl sulfate complexes approximately 120 to 140 nanometers in diameter.
Option C: Option C is incorrect; L-AmB is not a micellar suspension identical to AmBd — the liposomal structure and pharmacokinetics are fundamentally different.
Option D: Option D is incorrect; L-AmB consists of small unilamellar liposomes, not large multilamellar vesicles greater than 500 nanometers; ABLC (not L-AmB) distributes heavily to pulmonary tissue via MPS.

11. A patient with hepatosplenic candidiasis following chemotherapy for acute leukemia requires treatment with a lipid amphotericin B formulation. Which of the following best describes amphotericin B lipid complex (ABLC) and its potential advantage in this setting?

A) ABLC is preferred for hepatosplenic candidiasis because it inhibits candidal biofilm formation specifically in hepatic sinusoids through a mechanism not shared by L-AmB or ABLC
B) ABLC consists of ribbon-like lipid bilayer structures that are rapidly cleared from the circulation by the mononuclear phagocyte system, resulting in high drug concentrations in the liver, spleen, and lungs — organs that are the primary sites of hepatosplenic candidiasis
C) ABLC has superior antifungal efficacy compared to both AmBd and L-AmB in controlled clinical trials of hepatosplenic candidiasis, making it the guideline-recommended first-line agent for this specific indication
D) ABLC achieves high hepatosplenic drug concentrations because it is metabolized by hepatic cytochrome P450 enzymes to an active metabolite that accumulates in the reticuloendothelial cells of the liver and spleen
E) ABLC is formulated as small unilamellar liposomes identical in structure to L-AmB but at a higher drug concentration that favors accumulation in the liver and spleen due to the Kupffer cell phagocytic uptake of oversized liposomes

ANSWER: B

Rationale:

Amphotericin B lipid complex (ABLC; Abelcet) consists of ribbon-like lipid bilayer structures approximately 1.6 to 11 micrometers in length. Because of its large particle size, ABLC is rapidly cleared from the circulation by the mononuclear phagocyte system (MPS), resulting in high drug concentrations in the liver, spleen, and lungs — the organs with the highest density of MPS cells (Kupffer cells in the liver, macrophages in the spleen and pulmonary interstitium). This distribution pattern makes ABLC particularly well suited for infections involving these organs, such as hepatosplenic candidiasis. The standard dose is 5 mg/kg/day IV.

Option A: Option A is incorrect; the claim of a unique biofilm inhibition mechanism specific to ABLC in hepatic sinusoids is fabricated and not supported by evidence.
Option C: Option C is incorrect; ABLC has not demonstrated superior antifungal efficacy compared to AmBd or L-AmB in controlled clinical trials — all three lipid formulations and AmBd are considered non-inferior in efficacy, and the choice among them is driven by tolerability and distribution considerations rather than superior killing activity.
Option D: Option D is incorrect; ABLC is not metabolized by cytochrome P450 enzymes, and no active CYP-derived metabolite accumulates in reticuloendothelial cells — the MPS uptake is based on phagocytosis of lipid particles, not CYP metabolism.
Option E: Option E confuses the structure of ABLC with that of L-AmB; L-AmB consists of small unilamellar liposomes, while ABLC consists of ribbon-like lipid bilayer complexes, and the two formulations have distinct pharmacokinetic profiles.

12. When comparing the three available lipid-based amphotericin B formulations with respect to infusion-related reactions, which of the following is correct?

A) Liposomal amphotericin B (L-AmB) has the highest rate of acute infusion reactions of the three formulations, including fever, rigors, and bronchospasm, which limits its use to patients who have failed ABLC
B) All three lipid formulations — L-AmB, ABLC, and ABCD — have identical infusion reaction profiles, which is why infusion tolerability should not be a factor in formulation selection
C) Amphotericin B lipid complex (ABLC) has the highest infusion reaction rate of the three lipid formulations and is reserved for patients who cannot tolerate L-AmB or ABCD
D) Amphotericin B colloidal dispersion (ABCD) has the highest rate of acute infusion reactions of the three lipid formulations, including fever, rigors, and hypoxia, which substantially limits its clinical use when L-AmB or ABLC are available
E) All three lipid formulations have lower infusion reaction rates than amphotericin B deoxycholate but are equivalent to each other, so cost and availability should be the sole criteria for formulation selection

ANSWER: D

Rationale:

Amphotericin B colloidal dispersion (ABCD; Amphotec) is associated with the highest rate of acute infusion reactions of the three lipid amphotericin B formulations, including fever, rigors, and hypoxia. This substantial infusion-related toxicity is the primary reason ABCD is rarely selected in clinical practice when L-AmB or ABLC are available. ABCD consists of disk-shaped cholesteryl sulfate complexes approximately 120 to 140 nanometers in diameter; it is approved for invasive aspergillosis refractory to or intolerant of AmBd, but its poor infusion tolerability has limited its adoption. L-AmB has the best infusion tolerability among all AmB formulations and is the preferred formulation when cost is not a limiting factor.

Option A: Option A inverts the correct ranking: L-AmB has the best infusion tolerability, not the worst, and is not restricted to patients who have failed ABLC.
Option B: Option B is incorrect; the three lipid formulations do not have identical infusion reaction profiles — ABCD has substantially more infusion reactions than L-AmB or ABLC, and this difference is clinically important in formulation selection.
Option C: Option C incorrectly assigns the highest infusion reaction rate to ABLC; ABLC has moderate infusion reactions comparable to or slightly higher than L-AmB, but ABCD exceeds both.
Option E: Option E is incorrect in claiming that the three lipid formulations are equivalent in infusion tolerability; the differential infusion reaction rates among the formulations are well documented and directly influence clinical selection.

13. A clinical pharmacology fellow reviewing the evidence base for lipid amphotericin B formulations asks whether they have been demonstrated to be superior in antifungal efficacy to conventional amphotericin B deoxycholate. Which of the following is the most accurate characterization of the evidence?

A) Lipid formulations of amphotericin B have not been demonstrated to be superior to amphotericin B deoxycholate in antifungal efficacy in well-powered randomized controlled trials; they are non-inferior in efficacy with the primary advantage being reduced nephrotoxicity and improved tolerability
B) Liposomal amphotericin B has been demonstrated to be superior to amphotericin B deoxycholate in antifungal efficacy in multiple randomized controlled trials across all major fungal infection types, which is why it has replaced AmBd as the preferred formulation
C) The AmBiLoad trial established that liposomal amphotericin B at 10 mg/kg/day is significantly more effective than standard dose L-AmB at 3 mg/kg/day for invasive mold infections, supporting dose escalation for severe aspergillosis
D) Amphotericin B lipid complex has been shown to be superior to both AmBd and L-AmB in a landmark multicenter trial of invasive candidiasis in neutropenic patients, establishing ABLC as the preferred agent for this specific indication
E) Randomized controlled trials comparing lipid formulations to AmBd have consistently shown a 30 to 40% absolute improvement in all-cause mortality across all fungal infection categories, justifying their use as first-line therapy regardless of nephrotoxicity risk

ANSWER: A

Rationale:

A critical point in understanding the pharmacology of lipid amphotericin B formulations is that they have not been demonstrated to be superior in antifungal efficacy to conventional AmBd in well-powered randomized controlled trials. Rather, they have been shown to be non-inferior in efficacy with substantially improved tolerability, primarily through reduced nephrotoxicity. The choice of lipid formulation over AmBd is therefore driven by the need to prevent nephrotoxicity in patients at high risk — those with baseline renal impairment, concurrent nephrotoxins, transplant status, or anticipated prolonged courses — not by superior antifungal killing activity.

Option B: Option B overstates the evidence; lipid formulations have not demonstrated superior efficacy across all infection types and have not replaced AmBd through efficacy advantages.
Option C: Option C is incorrect because it mischaracterizes the AmBiLoad trial: this landmark trial actually showed that L-AmB at 10 mg/kg/day was not more effective than L-AmB at 3 mg/kg/day for invasive mold infections and produced substantially more toxicity at the higher dose — the trial supports standard dosing, not dose escalation.
Option D: Option D fabricates a landmark multicenter trial establishing ABLC superiority for invasive candidiasis in neutropenic patients; no such trial exists with this conclusion.
Option E: Option E fabricates a 30 to 40% absolute mortality reduction attributable to lipid formulations across all infection categories; this level of efficacy benefit has not been established in the published trial literature.

14. A patient receiving amphotericin B deoxycholate develops fever, rigors, and nausea beginning about 30 minutes into the infusion. The treating team asks whether this reaction represents an allergy to amphotericin B that would preclude future use. Which of the following best characterizes the mechanism and clinical significance of this reaction?

A) The reaction is an IgE-mediated type I hypersensitivity response involving mast cell degranulation and histamine release, which is a true allergic reaction that contraindicates all future amphotericin B use and requires immediate desensitization before retreatment
B) The reaction results from complement activation through the classical pathway triggered by the deoxycholate vehicle, which generates C3a and C5a anaphylatoxins causing direct mast cell degranulation; it is not IgE-mediated but is dose-dependent and will worsen with each subsequent infusion
C) The reaction is mediated through toll-like receptor 2 and toll-like receptor 4 signaling in monocytes and macrophages, with release of prostaglandins, IL-1, and TNF-alpha and complement activation via the alternative pathway; it is not IgE-mediated and does not contraindicate continued amphotericin B therapy
D) The reaction is a direct cytotoxic effect of amphotericin B on circulating erythrocytes and platelets, causing hemolysis and thrombocytopenia that generates the systemic inflammatory response; it predicts severe bone marrow toxicity and requires dose reduction before continuing therapy
E) The reaction represents amphotericin B-induced adrenal insufficiency causing acute cortisol deficiency with a cytokine-like picture; it is treated with IV hydrocortisone replacement rather than symptomatic premedication and resolves with adrenal supplementation

ANSWER: C

Rationale:

Acute infusion reactions to amphotericin B deoxycholate occur in up to 70% of patients and are mediated through toll-like receptor 2 (TLR-2) and toll-like receptor 4 (TLR-4) signaling in monocytes and macrophages, stimulating release of prostaglandins, interleukin-1 (IL-1), and tumor necrosis factor-alpha (TNF-alpha). Complement activation via the alternative pathway also contributes. Critically, the reaction is not IgE-mediated and therefore is not a true allergic reaction. It does not predict anaphylaxis and does not contraindicate continued amphotericin B use. Reactions typically diminish in severity with subsequent infusions as tolerance develops. Management includes premedication with acetaminophen and diphenhydramine 30 to 60 minutes before each infusion, with meperidine for established rigors.

Option A: Option A is incorrect; the reaction is not IgE-mediated and is not a type I hypersensitivity response — it does not contraindicate future AmB use and does not require desensitization.
Option B: Option B is incorrect in its conclusion: while it correctly identifies that the reaction involves complement and is not IgE-mediated, it incorrectly states that reactions will worsen with each subsequent infusion — in fact, tolerance typically develops with repeated dosing and reactions diminish over time.
Option D: Option D incorrectly attributes the infusion reaction to direct erythrocyte and platelet cytotoxicity; hemolysis is not the mechanism of the acute infusion syndrome.
Option E: Option E incorrectly invokes adrenal insufficiency as the mechanism; while amphotericin B can affect adrenal function with prolonged use, the acute infusion reaction is a cytokine-driven phenomenon, not a cortisol deficiency state.

15. A patient receiving amphotericin B deoxycholate develops severe rigors unresponsive to acetaminophen and diphenhydramine premedication. The nurse asks which agent is specifically indicated for treating established rigors in this setting. Which of the following is most appropriate?

A) Lorazepam 1 to 2 mg IV, which terminates rigors by potentiating GABA-A receptor inhibitory tone in the hypothalamic thermoregulatory center, resetting the fever threshold
B) Ketorolac 30 mg IV, which breaks rigors by inhibiting cyclooxygenase-mediated prostaglandin synthesis in the hypothalamus, directly opposing the prostaglandin E2-driven temperature elevation
C) Ondansetron 4 mg IV, which reduces rigors through 5-HT3 receptor antagonism in the area postrema and dorsal vagal complex, attenuating the nausea-associated autonomic component of the shivering response
D) Naloxone 0.4 mg IV, which paradoxically reduces amphotericin B-induced rigors by displacing endogenous dynorphin from kappa-opioid receptors in the spinal cord, thereby normalizing descending thermosensory modulation
E) Meperidine 25 to 50 mg IV, which is specifically effective for breaking established rigors by acting on mu-opioid receptors in the hypothalamus to reset the thermoregulatory set point

ANSWER: E

Rationale:

Meperidine 25 to 50 mg IV is specifically effective for terminating established rigors associated with amphotericin B infusion reactions. Its mechanism involves action on mu-opioid receptors in the hypothalamus that modulate the thermoregulatory set point, effectively interrupting the shivering response driven by the cytokine-mediated pyrogenic cascade. Meperidine is used specifically for rigors — not simply for fever or nausea — and its unique efficacy in this setting distinguishes it from other premedication agents such as acetaminophen (which addresses the antipyretic component) and diphenhydramine (which addresses histaminergic components).

Option A: Option A is incorrect; lorazepam is not used for AmB-associated rigors, and its proposed mechanism via GABA-A thermoregulatory tone is not an established pharmacological basis for treating drug-induced rigors.
Option B: Option B is incorrect; while ketorolac (an NSAID) may attenuate the prostaglandin-mediated component of the fever, it is not the agent specifically used for established rigors and does not have the rapid centrally acting antirigors efficacy of meperidine.
Option C: Option C is incorrect; ondansetron addresses nausea through 5-HT3 antagonism and is not the agent used for treating rigors in the setting of AmB infusion reactions.
Option D: Option D is incorrect; naloxone is an opioid antagonist and would be expected to block, not facilitate, the opioid-mediated pathway relevant to thermoregulation — its proposed mechanism is fabricated and its use would not be appropriate in this setting.

16. A patient on day 7 of amphotericin B deoxycholate therapy develops rising serum creatinine, hypokalemia, and inability to concentrate urine. Which of the following best describes the two distinct nephrotoxic mechanisms responsible for this clinical picture?

A) Amphotericin B causes nephrotoxicity through a single mechanism: direct glomerular basement membrane disruption by the polyene macrolide ring, producing protein leak and progressive glomerulonephritis with secondary tubular atrophy
B) Amphotericin B causes nephrotoxicity through two distinct mechanisms: afferent arteriolar vasoconstriction mediated by thromboxane A2 release that reduces glomerular filtration, and direct distal tubular epithelial damage through pore formation in cholesterol-containing apical membranes causing renal tubular acidosis, potassium wasting, and impaired urinary concentration
C) Amphotericin B causes nephrotoxicity primarily through renal prostaglandin depletion that causes papillary necrosis and collecting duct fibrosis, analogous to NSAID nephropathy but amplified by the high renal tissue concentrations achieved with IV dosing
D) Amphotericin B nephrotoxicity is mediated exclusively through distal tubular toxicity and produces no hemodynamic component; the rising creatinine reflects retrograde obstruction from tubular cast formation rather than reduction in glomerular filtration rate
E) Amphotericin B nephrotoxicity is an immune-mediated interstitial nephritis triggered by the deoxycholate vehicle rather than the amphotericin B molecule itself, which explains why switching to lipid formulations eliminates nephrotoxicity entirely

ANSWER: B

Rationale:

Amphotericin B deoxycholate nephrotoxicity involves two mechanistically distinct processes operating at different nephron sites. First, AmB causes afferent arteriolar vasoconstriction mediated through thromboxane A2 (TXA2) release and direct smooth muscle effects, reducing renal blood flow and glomerular filtration rate (GFR). This vasoconstrictive component is relatively rapidly reversible with drug discontinuation or dose reduction. Second, AmB directly damages distal tubular epithelial cells by forming pores in the apical cholesterol-containing membrane — the same mechanism by which it disrupts fungal membranes — causing type 1 (distal) renal tubular acidosis, urinary potassium wasting, urinary magnesium wasting, and impaired urinary concentrating ability. The tubular damage is dose-dependent, cumulative, and at high cumulative doses may be partially irreversible. Both components together explain the complete clinical picture of rising creatinine, hypokalemia, and impaired concentration.

Option A: Option A is incorrect; AmBd does not cause glomerulonephritis through basement membrane disruption — this describes a completely different class of nephropathy.
Option C: Option C is incorrect; renal prostaglandin depletion and papillary necrosis describe NSAID nephropathy, not AmBd toxicity; the mechanism is distinct.
Option D: Option D is incorrect because it denies the vasoconstrictive hemodynamic component that is well established and explains why GFR decreases beyond what tubular dysfunction alone would produce.
Option E: Option E is incorrect; while switching to lipid formulations substantially reduces nephrotoxicity, it does not eliminate it entirely, and the toxicity is attributable to amphotericin B itself interacting with membrane cholesterol, not solely to the deoxycholate vehicle.

17. Which of the following statements correctly describes the evidence-based strategy of sodium loading to reduce amphotericin B deoxycholate nephrotoxicity?

A) Administering 500 mL of normal saline immediately before each amphotericin B infusion is the most evidence-based strategy for reducing nephrotoxicity; the mechanism involves volume expansion that reduces tubuloglomerular feedback-mediated afferent arteriolar constriction, increases distal tubular sodium delivery, and dilutes free plasma drug concentration
B) Sodium loading is contraindicated during amphotericin B deoxycholate therapy because the added sodium chloride complexes with the deoxycholate vehicle and accelerates drug precipitation in the renal tubules, worsening rather than attenuating tubular crystalline deposits
C) Sodium loading with 500 mL of half-normal saline (0.45% NaCl) is recommended rather than isotonic saline, because hypotonic fluid better penetrates the renal tubular lumen and directly dilutes the luminal drug concentration at the site of tubular toxicity
D) Sodium loading is recommended only for the first three infusions of amphotericin B deoxycholate; after tolerance to the nephrotoxic effects develops, routine pre-hydration is no longer necessary and adds unnecessary volume load
E) Sodium loading with normal saline is contraindicated in patients receiving concomitant calcineurin inhibitors because the combination of volume expansion and calcineurin inhibitor-mediated sodium retention produces severe hypernatremia and paradoxically worsens renal vasoconstriction

ANSWER: A

Rationale:

Sodium loading — specifically the administration of 500 mL of 0.9% normal saline immediately before each amphotericin B infusion — is the most evidence-based strategy for reducing AmBd nephrotoxicity. Multiple prospective studies and meta-analyses have demonstrated that routine saline pre-hydration reduces the incidence and severity of nephrotoxicity without compromising antifungal efficacy. The mechanism operates through several complementary pathways: volume expansion reduces tubuloglomerular feedback-mediated afferent arteriolar vasoconstriction, increased sodium delivery to the distal tubule competes with tubular potassium wasting, and intravascular volume expansion dilutes free plasma drug concentration, reducing renal tubular epithelial exposure. Sodium loading is contraindicated only in patients with severe heart failure, pulmonary edema, or anasarca where the volume load cannot be tolerated — in these patients, a lipid formulation should be used from the outset rather than AmBd with sodium loading.

Option B: Option B is incorrect; the mechanism by which sodium loading is beneficial is exactly the opposite of what is described — it does not accelerate tubular precipitation but rather reduces nephrotoxicity through the mechanisms described above.
Option C: Option C is incorrect; isotonic normal saline (0.9% NaCl), not half-normal saline, is used for sodium loading — the benefit is derived from the volume and sodium content, and half-normal saline provides a weaker osmotic volume expansion.
Option D: Option D is incorrect; sodium loading should be continued for every infusion throughout the course of AmBd therapy — there is no established tolerance to nephrotoxicity that obviates the need for pre-hydration.
Option E: Option E fabricates a dangerous contraindication; sodium loading is particularly indicated — not contraindicated — in patients receiving calcineurin inhibitors, given the additive nephrotoxicity of those agents with AmBd.

18. A patient receiving amphotericin B deoxycholate has a serum potassium of 2.8 mEq/L despite receiving 120 mEq of IV potassium chloride over 24 hours. Repeat labs show serum magnesium of 1.2 mg/dL. Which of the following best explains the refractory hypokalemia and the required intervention?

A) The refractory hypokalemia is due to amphotericin B-induced secondary hyperaldosteronism; the correct intervention is spironolactone to block the mineralocorticoid receptor driving potassium wasting in the collecting duct
B) The refractory hypokalemia reflects gastrointestinal potassium loss from amphotericin B-induced secretory diarrhea; the correct intervention is oral rehydration solution rather than IV potassium chloride
C) The refractory hypokalemia is caused by direct amphotericin B inhibition of the Na-K-ATPase pump in the proximal tubule, preventing normal potassium reabsorption; the correct intervention is amiloride to block apical sodium entry and reduce the electrochemical driving force for potassium loss
D) Hypomagnesemia causes refractory hypokalemia because magnesium is required for normal function of the renal outer medullary potassium channel responsible for potassium reabsorption in the distal nephron; magnesium must be repleted before potassium wasting can be corrected
E) The refractory hypokalemia reflects transcellular redistribution of potassium into muscle cells driven by amphotericin B-induced alkalosis; the correct intervention is acetazolamide to correct the metabolic alkalosis before potassium replacement can be effective

ANSWER: D

Rationale:

Amphotericin B deoxycholate causes both potassium and magnesium wasting through distal tubular toxicity. The critical clinical principle illustrated in this case is that hypomagnesemia produces refractory hypokalemia: magnesium is required for normal function of the renal outer medullary potassium (ROMK) channel responsible for potassium reabsorption in the distal nephron. When serum magnesium is depleted, ROMK channel function is impaired, potassium reabsorption in the distal tubule is reduced, and urinary potassium wasting continues regardless of the amount of potassium administered. This means that potassium deficits cannot be corrected until hypomagnesemia is addressed. The correct management is to provide magnesium supplementation (oral magnesium oxide or IV magnesium sulfate) concurrently with continued potassium replacement.

Option A: Option A is incorrect; amphotericin B nephrotoxicity does not cause secondary hyperaldosteronism, and the refractory nature of the hypokalemia in the presence of hypomagnesemia is explained by ROMK channel impairment, not aldosterone excess.
Option B: Option B is incorrect; the mechanism of AmBd-induced hypokalemia is renal wasting through tubular dysfunction, not secretory GI diarrhea.
Option C: Option C is incorrect; the mechanism of proximal tubule Na-K-ATPase inhibition with amiloride treatment is not the pharmacological basis of AmBd tubular toxicity, which operates at the distal tubule through membrane pore formation.
Option E: Option E is incorrect; AmBd does not typically cause metabolic alkalosis — it more commonly causes distal renal tubular acidosis, and transcellular redistribution due to alkalosis is not the mechanism of potassium wasting in this setting.

19. A medical student asks why nystatin, which shares the same mechanism of action as amphotericin B, cannot be used for invasive systemic fungal infections. Which of the following correctly explains this limitation?

A) Nystatin is not effective against the Candida species and Cryptococcus neoformans that most commonly cause invasive fungal infections; its spectrum is limited to dermatophytes and dimorphic fungi, making it inappropriate for systemic candidiasis or cryptococcal meningitis
B) Nystatin is rapidly degraded by hepatic cytochrome P450 3A4 enzymes after absorption, resulting in a terminal half-life of less than 30 minutes that precludes therapeutic serum concentrations even after IV administration
C) Nystatin is essentially insoluble in aqueous solution at physiological pH and cannot be formulated for intravenous administration without producing severe systemic toxicity; it therefore exists clinically only as topical and oral non-absorbed preparations
D) Nystatin penetrates fungal cell membranes less efficiently than amphotericin B because it has a tetraene rather than heptaene polyene chain, which reduces its ergosterol binding affinity to levels insufficient for treatment of invasive infection
E) Nystatin undergoes irreversible binding to plasma proteins at greater than 99.9% and therefore has effectively zero free drug concentration in blood, preventing distribution to sites of fungal infection despite adequate IV dosing

ANSWER: C

Rationale:

Nystatin is essentially completely insoluble in aqueous solution at physiological pH. This insolubility means it cannot be formulated for intravenous administration without producing severe systemic toxicity. The original IV nystatin formulations developed in the 1950s were abandoned because of unacceptable systemic toxicity. A liposomal nystatin formulation was subsequently developed and showed promise in clinical trials with reduced nephrotoxicity, but it was not approved by the FDA and remains investigational. Nystatin therefore exists in clinical practice exclusively as topical preparations (cream, ointment, powder) and as oral formulations (suspension, tablets) that are not absorbed from the gastrointestinal tract, limiting its use to treatment of mucosal and cutaneous candidiasis.

Option A: Option A is incorrect; nystatin's antifungal spectrum against Candida species and other fungi is comparable to amphotericin B — the limitation is not a narrow spectrum but rather the inability to safely administer it systemically.
Option B: Option B is incorrect; nystatin's limitation is not rapid hepatic CYP3A4 degradation — the problem is the inability to formulate it safely for IV use due to aqueous insolubility and systemic toxicity, not a pharmacokinetic elimination issue.
Option D: Option D is incorrect as a complete explanation: while it correctly notes a true structural difference between nystatin (tetraene) and AmB (heptaene), this structural difference does not translate into insufficient ergosterol binding affinity for clinical efficacy — the antifungal spectrum of nystatin is comparable to AmB, and aqueous insolubility, not reduced ergosterol affinity, is the true barrier to systemic use.
Option E: Option E fabricates a protein-binding mechanism for nystatin's systemic limitation; plasma protein binding is not the reason nystatin cannot be used for invasive infection.

20. An immunocompromised patient on prolonged azole prophylaxis develops breakthrough Candida glabrata fungemia. Susceptibility testing reveals elevated amphotericin B minimum inhibitory concentrations. Which of the following best explains the molecular mechanism of acquired polyene resistance in this clinical context?

A) Prolonged azole exposure selects for overexpression of Candida CDR1 and MDR1 efflux pump genes that actively export amphotericin B from the fungal cell before it can bind ergosterol, simultaneously conferring resistance to both azoles and polyenes
B) Acquired polyene resistance results from mutation in the FKS1 gene encoding the beta-1,3-glucan synthase catalytic subunit, which reduces cell wall permeability and prevents amphotericin B from reaching ergosterol in the inner leaflet of the fungal membrane
C) Amphotericin B resistance develops through upregulation of the fungal HSP90 heat shock protein, which stabilizes mutant ergosterol biosynthesis enzymes against degradation and maintains sufficient ergosterol content to prevent the cellular toxicity of pore formation
D) Prolonged azole exposure induces expression of the Candida ERG25 gene encoding C-4 methyl sterol oxidase, which converts ergosterol to a modified form with higher amphotericin B binding affinity, paradoxically increasing susceptibility rather than resistance
E) Mutations in ERG3, encoding C-5 sterol desaturase, cause accumulation of 14-alpha-methylfecosterol — a toxic intermediate that cannot substitute for ergosterol and also cannot bind amphotericin B — effectively eliminating the drug's membrane target; these mutations can be co-selected by prolonged azole exposure because both drug classes target the ergosterol biosynthesis pathway

ANSWER: E

Rationale:

The primary mechanism of acquired polyene resistance involves mutations in ergosterol biosynthesis genes, particularly ERG3 (encoding C-5 sterol desaturase) and ERG11 (encoding lanosterol 14-alpha-demethylase). ERG3 mutations cause accumulation of 14-alpha-methylfecosterol, an abnormal sterol intermediate that cannot functionally substitute for ergosterol in the membrane and also cannot bind amphotericin B. The result is a fungal cell membrane depleted of the drug's pharmacological target. A clinically important feature is that these ERG gene mutations can be co-selected by prolonged azole exposure: azoles target lanosterol 14-alpha-demethylase (ERG11) in the same ergosterol biosynthesis pathway, and mutations selected to reduce azole efficacy can simultaneously alter ergosterol content and reduce AmB susceptibility. This explains why organisms with acquired azole resistance — particularly Candida glabrata following prolonged azole prophylaxis — may show reduced polyene susceptibility on testing.

Option A: Option A is incorrect; CDR1 and MDR1 efflux pumps are major determinants of azole resistance in Candida but do not efflux amphotericin B, which acts at the membrane surface rather than requiring intracellular transport.
Option B: Option B is incorrect; FKS1 mutations confer echinocandin resistance by altering the glucan synthase target — this mechanism is entirely distinct from polyene resistance, which depends on ergosterol.
Option C: Option C is incorrect; HSP90 upregulation stabilizing ergosterol biosynthesis enzymes is not an established mechanism of clinical polyene resistance, though HSP90 has been studied in the context of azole tolerance.
Option D: Option D fabricates an ERG25-mediated mechanism that paradoxically increases susceptibility — this does not describe any established resistance pathway.

21. The combination of amphotericin B and flucytosine (5-fluorocytosine) is the standard induction regimen for cryptococcal meningitis. Which of the following best explains the pharmacodynamic basis for this combination?

A) Flucytosine inhibits dihydrofolate reductase in the fungal cell, blocking purine synthesis and creating metabolic starvation that sensitizes Cryptococcus neoformans to amphotericin B-mediated pore formation by reducing the energy available for membrane repair
B) Amphotericin B increases fungal cell membrane permeability through pore formation, enhancing uptake of flucytosine into the fungal cell, where it is converted to 5-fluorouracil and incorporated into fungal RNA and DNA; the combination achieves fungicidal activity at concentrations lower than either agent alone
C) The combination is pharmacokinetically synergistic because flucytosine inhibits cytochrome P450 3A4 in the choroid plexus, increasing local amphotericin B concentrations in the CSF by preventing its oxidative inactivation at the blood-brain barrier
D) Flucytosine chelates ergosterol in the fungal membrane, creating structural destabilization that increases the number of binding sites available for amphotericin B and potentiates pore assembly beyond what either agent achieves independently
E) The combination is synergistic because amphotericin B and flucytosine both inhibit ergosterol biosynthesis at sequential steps in the pathway, producing additive depletion of membrane ergosterol content and progressively eliminating the structural target for both agents

ANSWER: B

Rationale:

The pharmacodynamic synergy between amphotericin B and flucytosine (5-FC) against Cryptococcus neoformans is well established and mechanistically rational. Amphotericin B forms transmembrane pores in the fungal cell membrane, increasing membrane permeability. This enhanced permeability facilitates uptake of 5-FC into the fungal cell, where it is deaminated to 5-fluorouracil (5-FU) by fungal cytosine deaminase and subsequently converted to metabolites that are incorporated into fungal RNA (disrupting protein synthesis) and converted to 5-fluoro-2-deoxyuridine monophosphate (5-FdUMP) that inhibits thymidylate synthase (blocking DNA synthesis). The combination is fungicidal against Cryptococcus at concentrations lower than either agent alone, and clinical trial data demonstrate superior CSF sterilization rates compared to monotherapy with either agent. The WHO 2022 guidelines for cryptococcal meningitis recommend AmB plus 5-FC as a key component of induction regimens.

Option A: Option A is incorrect; flucytosine does not inhibit dihydrofolate reductase — that is the mechanism of trimethoprim, not 5-FC. Flucytosine acts on RNA and DNA synthesis through conversion to 5-FU metabolites.
Option C: Option C is incorrect; flucytosine does not inhibit CYP3A4, and AmB is not metabolized by CYP enzymes — there is no pharmacokinetic component to this synergy, only a pharmacodynamic one.
Option D: Option D is incorrect; flucytosine does not chelate ergosterol — it has no mechanism of direct ergosterol interaction.
Option E: Option E is incorrect; neither amphotericin B nor flucytosine inhibits ergosterol biosynthesis — AmB binds ergosterol already in the membrane, and 5-FC acts on nucleic acid synthesis, not the ergosterol pathway.

22. An infectious disease consultant is asked to recommend the appropriate amphotericin B formulation for a renal transplant recipient with a baseline creatinine of 1.8 mg/dL who requires treatment for invasive mucormycosis. Which of the following best represents the correct prescribing decision and its rationale?

A) A lipid amphotericin B formulation should be used from the outset rather than conventional amphotericin B deoxycholate, because transplant recipient status, concurrent calcineurin inhibitor use, and anticipated prolonged treatment duration together meet multiple indications for lipid formulation initiation without waiting for nephrotoxicity to develop
B) Conventional amphotericin B deoxycholate should be initiated at 1.0 mg/kg/day with serial creatinine monitoring, and the formulation should be switched to liposomal amphotericin B only if serum creatinine doubles from baseline, because proactive lipid formulation use is not supported by current guidelines for transplant recipients
C) Liposomal amphotericin B is the correct choice for mucormycosis in all clinical settings regardless of patient risk factors, because it has been demonstrated to be superior in antifungal efficacy to AmBd specifically against the Mucorales in at least two randomized controlled trials
D) Amphotericin B lipid complex should be chosen over liposomal amphotericin B for this patient because ABLC has demonstrated superior nephroprotective properties in transplant recipients compared to L-AmB in head-to-head randomized trials and is the guideline-recommended agent for calcineurin inhibitor-treated patients
E) The combination of conventional amphotericin B deoxycholate plus sodium loading should be used for the first two weeks, transitioning to liposomal amphotericin B for any additional weeks of therapy needed, because this sequential strategy balances efficacy and cost while providing nephroprotection for the prolonged treatment phase

ANSWER: A

Rationale:

This patient meets multiple independent indications for initiating a lipid amphotericin B formulation at the outset rather than starting with conventional AmBd and waiting for nephrotoxicity: solid organ transplant recipient status, concurrent calcineurin inhibitor use (tacrolimus or cyclosporine adds pharmacodynamic nephrotoxicity to AmBd's intrinsic tubular toxicity), and anticipated prolonged treatment duration for mucormycosis (which typically requires weeks to months of antifungal therapy plus surgical debridement). The principle that lipid formulation use should be proactive rather than reactive is well established — tubular damage from even brief AmBd exposure can be cumulative and partially irreversible, making the strategy of starting with AmBd and planning to switch if nephrotoxicity develops suboptimal. L-AmB at 5 mg/kg/day is the preferred regimen for mucormycosis based on registry data.

Option B: Option B incorrectly recommends reactive switching after creatinine doubling; in a transplant recipient on calcineurin inhibitors with prolonged anticipated therapy, proactive lipid formulation use is the correct strategy.
Option C: Option C overstates the evidence for L-AmB superiority over AmBd in mucormycosis; while L-AmB is preferred, the evidence is from retrospective and registry data, not well-powered randomized controlled trials demonstrating superior efficacy.
Option D: Option D fabricates head-to-head randomized trial data establishing ABLC superiority over L-AmB in transplant recipients — no such trials exist, and L-AmB remains the preferred lipid formulation in most settings.
Option E: Option E describes a sequential AmBd-to-L-AmB strategy that is explicitly the approach the prescribing framework advises against for high-risk patients; the decision to use a lipid formulation should be made before initiating therapy, not reactively.